Innovent Financial Statements From 2010 to 2024
| IVBXF Stock | USD 4.86 0.03 0.62% |
Check Innovent Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innovent Biologics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Innovent financial statements analysis is a perfect complement when working with Innovent Biologics Valuation or Volatility modules.
Innovent |
Innovent Biologics Company Profit Margin Analysis
Innovent Biologics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Innovent Biologics Profit Margin | (0.68) % |
Most of Innovent Biologics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovent Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Innovent Biologics has a Profit Margin of -0.6754%. This is 93.98% lower than that of the Healthcare sector and 97.07% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 46.82% lower than that of the firm.
Innovent Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innovent Biologics's current stock value. Our valuation model uses many indicators to compare Innovent Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innovent Biologics competition to find correlations between indicators driving Innovent Biologics's intrinsic value. More Info.Innovent Biologics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innovent Biologics' earnings, one of the primary drivers of an investment's value.About Innovent Biologics Financial Statements
Innovent Biologics stakeholders use historical fundamental indicators, such as Innovent Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Innovent Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innovent Biologics' assets and liabilities are reflected in the revenues and expenses on Innovent Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innovent Biologics. Please read more on our technical analysis and fundamental analysis pages.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.